BioMarin ends year with $4.8bn play for Amicus BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market

BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market. pharmaphorum.com/news/biomari...
#BiotechDeals #MergersAndAcquisitions #LifeSciences #PharmaNews #BiotechBusiness